{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:56:16Z","timestamp":1793361376818,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.mayocp.2022.06.036","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T10:05:12Z","timestamp":1664791512000},"page":"1808-1823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-1629","authenticated-orcid":false,"given":"Kamal","family":"Awad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-7253","authenticated-orcid":false,"given":"Mahmoud Mohamed","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8737-2453","authenticated-orcid":false,"given":"Joanna","family":"Lewek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-1911","authenticated-orcid":false,"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mayocp.2022.06.036_bib1","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12)(pt 2","key":"10.1016\/j.mayocp.2022.06.036_bib2","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1301\/nr.2007.dec.S152-S156","article-title":"Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders","volume":"65","author":"Pradhan","year":"2007","journal-title":"Nutr Rev"},{"issue":"8","key":"10.1016\/j.mayocp.2022.06.036_bib3","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2016.01.025","article-title":"Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?","volume":"150","author":"Gao","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.mayocp.2022.06.036_bib4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/heartjnl-2018-314216","article-title":"Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies","volume":"105","author":"Jayedi","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.mayocp.2022.06.036_bib5","doi-asserted-by":"crossref","first-page":"103062","DOI":"10.1016\/j.ebiom.2020.103062","article-title":"Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes","volume":"61","author":"Bowker","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.mayocp.2022.06.036_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","article-title":"Chronic subclinical inflammation as part of\u00a0the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)","volume":"102","author":"Festa","year":"2000","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.mayocp.2022.06.036_bib7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9568","key":"10.1016\/j.mayocp.2022.06.036_bib8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk","volume":"369","author":"Schmieder","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mayocp.2022.06.036_bib9","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/01.ATV.0000021412.56621.A2","article-title":"Vascular inflammation and the renin-angiotensin system","volume":"22","author":"Brasier","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1)(pt 2","key":"10.1016\/j.mayocp.2022.06.036_bib10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.HYP.29.1.366","article-title":"Angiotensin II signaling in vascular smooth muscle: new concepts","volume":"29","author":"Griendling","year":"1997","journal-title":"Hypertension"},{"issue":"82","key":"10.1016\/j.mayocp.2022.06.036_bib11","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1046\/j.1523-1755.62.s82.4.x","article-title":"Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney","volume":"62","author":"Ruiz-Ortega","year":"2002","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"10.1016\/j.mayocp.2022.06.036_bib12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/01.RES.84.6.695","article-title":"Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-\u03baB transcription factors","volume":"84","author":"Han","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.mayocp.2022.06.036_bib13","doi-asserted-by":"crossref","first-page":"104916","DOI":"10.1016\/j.phrs.2020.104916","article-title":"Clinical approach to the inflammatory etiology of cardiovascular diseases","volume":"159","author":"Ruscica","year":"2020","journal-title":"Pharmacol Res"},{"issue":"17","key":"10.1016\/j.mayocp.2022.06.036_bib14","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.mayocp.2022.06.036_bib15","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.mayocp.2022.06.036_bib16","series-title":"Empirical Assessment of Within-Arm Correlation Imputation in Trials of Continuous Outcomes","author":"Balk","year":"2012"},{"issue":"7","key":"10.1016\/j.mayocp.2022.06.036_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.mayocp.2022.06.036_bib18","series-title":"Methods Guide for Effectiveness and Comparative Effectiveness Reviews","year":"2008"},{"key":"10.1016\/j.mayocp.2022.06.036_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"7521","key":"10.1016\/j.mayocp.2022.06.036_bib20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/bmj.331.7521.903","article-title":"Standard deviations and standard errors","volume":"331","author":"Altman","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.mayocp.2022.06.036_bib21","author":"Higgins"},{"issue":"2","key":"10.1016\/j.mayocp.2022.06.036_bib22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clin Epidemiol Global Health"},{"issue":"7109","key":"10.1016\/j.mayocp.2022.06.036_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.mayocp.2022.06.036_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/HYPERTENSIONAHA.111.173542","article-title":"High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-\u03b3 target genes in patients with the metabolic syndrome","volume":"58","author":"B\u00e4hr","year":"2011","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.mayocp.2022.06.036_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/hrt.2004.036509","article-title":"Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina","volume":"91","author":"Biasucci","year":"2005","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.mayocp.2022.06.036_bib26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/j.ajkd.2005.02.022","article-title":"Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients","volume":"45","author":"Ichihara","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2022.06.036_bib27","first-page":"26","article-title":"Enalapril improves endothelial function in patients with migraine: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Javanmard","year":"2011","journal-title":"J\u00a0Res Med Sci"},{"issue":"3","key":"10.1016\/j.mayocp.2022.06.036_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diabres.2010.04.018","article-title":"Effect of high-dose valsartan on inflammatory and lipid parameters in patients with type 2 diabetes and hypertension","volume":"89","author":"Kintscher","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.mayocp.2022.06.036_bib29","first-page":"514","article-title":"Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease","volume":"60","author":"Krysiak","year":"2008","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.mayocp.2022.06.036_bib30","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1734-1140(11)70634-X","article-title":"Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure","volume":"63","author":"Krysiak","year":"2011","journal-title":"Pharmacol Rep"},{"issue":"6","key":"10.1016\/j.mayocp.2022.06.036_bib31","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S1734-1140(12)70944-1","article-title":"Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure","volume":"64","author":"Krysiak","year":"2012","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.mayocp.2022.06.036_bib32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/etm.2011.305","article-title":"Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction","volume":"2","author":"Dess\u00ec","year":"2011","journal-title":"Exp Ther Med"},{"issue":"3","key":"10.1016\/j.mayocp.2022.06.036_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/sj.jhh.1002310","article-title":"Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus","volume":"22","author":"Marketou","year":"2008","journal-title":"J\u00a0Hum Hypertens"},{"issue":"1","key":"10.1016\/j.mayocp.2022.06.036_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MAT.0b013e3181c1d830","article-title":"Is systemic inflammation of hemodialysis patients improved with the use of enalapril? Results of a randomized, double-blinded, placebo-controlled clinical trial","volume":"56","author":"Ordaz-Medina","year":"2010","journal-title":"ASAIO J"},{"issue":"4","key":"10.1016\/j.mayocp.2022.06.036_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/CS20110284","article-title":"Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose","volume":"122","author":"Perlstein","year":"2012","journal-title":"Clin Sci (Lond)"},{"issue":"7","key":"10.1016\/j.mayocp.2022.06.036_bib36","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/CIRCRESAHA.114.302420","article-title":"Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication","volume":"114","author":"Ahimastos","year":"2014","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.mayocp.2022.06.036_bib37","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.2337\/db06-0827","article-title":"Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy","volume":"55","author":"Persson","year":"2006","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.mayocp.2022.06.036_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/hdi.12436","article-title":"Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: a randomized double blind placebo controlled trial (SAFIR study)","volume":"21","author":"Peters","year":"2017","journal-title":"Hemodial Int"},{"key":"10.1016\/j.mayocp.2022.06.036_bib39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ahj.2015.12.021","article-title":"Effect of angiotensin II type I receptor blockade with valsartan on carotid artery atherosclerosis: a double blind randomized clinical trial comparing valsartan and placebo (EFFERVESCENT)","volume":"174","author":"Ramadan","year":"2016","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.mayocp.2022.06.036_bib40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.CIR.0000153272.48711.B9","article-title":"Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study","volume":"111","author":"Sola","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2022.06.036_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1559-4572.2008.07117.x","article-title":"Effects of angiotensin-converting enzyme inhibitor therapy on levels of inflammatory markers in response to exercise-induced stress: studies in the metabolic syndrome","volume":"3","author":"Vaccari","year":"2008","journal-title":"J\u00a0Cardiometab Syndr"},{"issue":"10","key":"10.1016\/j.mayocp.2022.06.036_bib42","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1097\/HJH.0b013e32834a7667","article-title":"Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism","volume":"29","author":"van der Zijl","year":"2011","journal-title":"J\u00a0Hypertens"},{"issue":"4","key":"10.1016\/j.mayocp.2022.06.036_bib43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1078-5884(03)00084-4","article-title":"Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1","volume":"26","author":"van Haelst","year":"2003","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"7","key":"10.1016\/j.mayocp.2022.06.036_bib44","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S0828-282X(09)70508-2","article-title":"Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results","volume":"25","author":"Verma","year":"2009","journal-title":"Can J Cardiol"},{"issue":"7","key":"10.1016\/j.mayocp.2022.06.036_bib45","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.ATV.0000022847.38083.B6","article-title":"Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction","volume":"22","author":"Wassmann","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.06.036_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cardfail.2006.10.013","article-title":"Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure","volume":"13","author":"White","year":"2007","journal-title":"J\u00a0Card Fail"},{"issue":"4","key":"10.1016\/j.mayocp.2022.06.036_bib47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1358863x06072221","article-title":"The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction","volume":"11","author":"Bank","year":"2006","journal-title":"Vasc Med"},{"issue":"9","key":"10.1016\/j.mayocp.2022.06.036_bib48","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/01.hjh.0000242415.73406.17","article-title":"Telmisartan inhibits \u03b22-integrin MAC-1 expression in human T-lymphocytes","volume":"24","author":"Link","year":"2006","journal-title":"J\u00a0Hypertens"},{"issue":"4","key":"10.1016\/j.mayocp.2022.06.036_bib49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/ijmr.IJMR_640_19","article-title":"A\u00a0comparative study on the anti-inflammatory effect of angiotensin-receptor blockers & statins on rheumatoid arthritis disease activity","volume":"152","author":"Mostafa","year":"2020","journal-title":"Indian J Med Res"},{"issue":"3","key":"10.1016\/j.mayocp.2022.06.036_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2796.2005.01448.x","article-title":"Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition","volume":"257","author":"Bohm","year":"2005","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2022.06.036_bib51","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2008.08.042","article-title":"ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study","volume":"204","author":"Ceconi","year":"2009","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.mayocp.2022.06.036_bib52","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00213-019-5181-z","article-title":"Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial","volume":"236","author":"Fan","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.mayocp.2022.06.036_bib53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2337\/dc07-0711","article-title":"Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms","volume":"31","author":"Fernandez","year":"2008","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.mayocp.2022.06.036_bib54","first-page":"330","article-title":"Influence of preventive therapy with quinapril on IL-6 level in patients with chronic stable angina","volume":"59","author":"Gibas","year":"2007","journal-title":"Pharmacol Rep"},{"issue":"6","key":"10.1016\/j.mayocp.2022.06.036_bib55","doi-asserted-by":"crossref","first-page":"e39930","DOI":"10.1371\/journal.pone.0039930","article-title":"Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial","volume":"7","author":"Goossens","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.mayocp.2022.06.036_bib56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11883-014-0435-z","article-title":"Inflammation and cardiovascular disease: from pathogenesis to therapeutic target","volume":"16","author":"Golia","year":"2014","journal-title":"Curr Atheroscler Rep"},{"issue":"17","key":"10.1016\/j.mayocp.2022.06.036_bib57","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/eurheartj\/ehu071","article-title":"Non-coronary atherosclerosis","volume":"35","author":"Gallino","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.mayocp.2022.06.036_bib58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.mayocp.2022.06.036_bib59","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/01.ATV.19.7.1623","article-title":"Angiotensin induces inflammatory activation of human vascular smooth muscle cells","volume":"19","author":"Kranzh\u00f6fer","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2-3","key":"10.1016\/j.mayocp.2022.06.036_bib60","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0014-5793(94)00531-1","article-title":"Activation of human peripheral monocytes by angiotensin II","volume":"347","author":"Hahn","year":"1994","journal-title":"FEBS Lett"},{"issue":"9","key":"10.1016\/j.mayocp.2022.06.036_bib61","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1161\/01.RES.83.9.952","article-title":"Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells","volume":"83","author":"Chen","year":"1998","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.mayocp.2022.06.036_bib62","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.100.9.899","article-title":"Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein","volume":"100","author":"Morawietz","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.mayocp.2022.06.036_bib63","doi-asserted-by":"crossref","first-page":"752406","DOI":"10.1155\/2009\/752406","article-title":"The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies","volume":"2009","author":"Montecucco","year":"2009","journal-title":"Mediators Inflamm"},{"issue":"3","key":"10.1016\/j.mayocp.2022.06.036_bib64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.15829\/1728-8800-2012-3-102-112","article-title":"Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil","volume":"11","author":"Mason","year":"2012","journal-title":"Cardiovasc Ther Prev"},{"issue":"18","key":"10.1016\/j.mayocp.2022.06.036_bib65","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","article-title":"Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects","volume":"339","author":"Gainer","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"6)(pt 2","key":"10.1016\/j.mayocp.2022.06.036_bib66","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.HYP.13.6.658","article-title":"Endothelium and control of vascular function. State of the art lecture","volume":"13","author":"Vanhoutte","year":"1989","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.mayocp.2022.06.036_bib67","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1124\/jpet.106.104026","article-title":"Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans","volume":"318","author":"Murphey","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.mayocp.2022.06.036_bib68","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10557-007-6041-3","article-title":"ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial","volume":"21","author":"Bots","year":"2007","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2022.06.036_bib69","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","article-title":"Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans","volume":"95","author":"Hornig","year":"1997","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mayocp.2022.06.036_bib70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40119-019-00150-w","article-title":"A\u00a0review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril","volume":"8","author":"Ancion","year":"2019","journal-title":"Cardiol Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2022.06.036_bib71","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40256-016-0173-4","article-title":"Unraveling the pivotal role of bradykinin in ACE inhibitor activity","volume":"16","author":"Taddei","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"10.1016\/j.mayocp.2022.06.036_bib72","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jss.2010.04.005","article-title":"Cardiomyocytic apoptosis limited by bradykinin via restoration of nitric oxide after cardioplegic arrest","volume":"163","author":"Yeh","year":"2010","journal-title":"J\u00a0Surg Res"},{"issue":"3","key":"10.1016\/j.mayocp.2022.06.036_bib73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.mayocp.2022.06.036_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719868134","article-title":"The place of ARBs in heart failure therapy: is aldosterone suppression the key?","volume":"13","author":"Markan","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2022.06.036_bib75","first-page":"211","article-title":"Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction","volume":"15","author":"Tsikouris","year":"2004","journal-title":"Coron Artery Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2022.06.036_bib76","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.5114\/aoms.2020.100304","article-title":"Statins and C-reactive protein: in silico evidence on direct interaction","volume":"16","author":"Shakour","year":"2020","journal-title":"Arch Med Sci"},{"issue":"4","key":"10.1016\/j.mayocp.2022.06.036_bib77","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/bcp.15041","article-title":"Efficacy and safety of colchicine in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials","volume":"88","author":"Byty\u00e7i","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.mayocp.2022.06.036_bib78","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pcad.2021.06.010","article-title":"Impact of nutraceuticals on markers of systemic inflammation: potential relevance to cardiovascular diseases\u2014a position paper from the International Lipid Expert Panel (ILEP)","volume":"67","author":"Ruscica","year":"2021","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.mayocp.2022.06.036_bib79","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijcard.2012.01.104","article-title":"Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials","volume":"156","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.mayocp.2022.06.036_bib80","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11883-021-00932-5","article-title":"Colchicine and cardiovascular outcomes: a critical appraisal of recent studies","volume":"23","author":"Banach","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"34","key":"10.1016\/j.mayocp.2022.06.036_bib81","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.mayocp.2022.06.036_bib82","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1681\/ASN.2011030305","article-title":"Inflammation and the paradox of racial differences in dialysis survival","volume":"22","author":"Crews","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.06.036_bib83","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000323972","article-title":"Racial and ethnic differences in mortality of hemodialysis patients: role of dietary and nutritional status and inflammation","volume":"33","author":"Noori","year":"2011","journal-title":"Am J Nephrol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622004396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622004396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T15:42:17Z","timestamp":1666798937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619622004396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0025619622004396"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.06.036","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}